✦ LIBER ✦

A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer

✍ Scribed by Joseph S. Chan; Tomasz M. Beer; David I. Quinn; Jacek K. Pinski; Mark Garzotto; Mitchell Sokoloff; Daniel R. Dehaze; Christopher W. Ryan

Book ID: 109054349
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 150 KB
Volume: 102
Category: Article
ISSN: 1464-4096
DOI: 10.1111/j.1464-410x.2008.08017.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

HIGH DOSE PULSE CALCITRIOL, DOCETAXEL AN

HIGH DOSE PULSE CALCITRIOL, DOCETAXEL AND ESTRAMUSTINE FOR ANDROGEN INDEPENDENT PROSTATE CANCER: A PHASE I/II STUDY

✍ TIFFANY, NATASHA M.; RYAN, CHRISTOPHER W.; GARZOTTO, MARK; WERSINGER, EMILY M.; 📂 Article 📅 2005 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 71 KB

Phase II Study of Low Dose and High Dose

Phase II Study of Low Dose and High Dose Conjugated Estrogen for Androgen Independent Prostate Cancer

✍ Pomerantz, Mark; Manola, Judith; Taplin, Mary-Ellen; Bubley, Glenn; Inman, Marga 📂 Article 📅 2007 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 200 KB

Phase II trial of high-dose, intermitten

Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer

✍ Donald L. Trump; Douglas M. Potter; Josephia Muindi; Adam Brufsky; Candace S. Jo 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

Phase III Study of Mitoxantrone Plus Low

Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate Cancer

✍ BERRY, WILLIAM; DAKHIL, SHAKER; MODIANO, MANUEL; GREGURICH, MARYANN; ASMAR, LINA 📂 Article 📅 2002 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 82 KB

890 PUBLICATION Combination chemotherapy

890 PUBLICATION Combination chemotherapy in androgen-independent metastatic prostate cancer. a phase II study with docetaxel and ifosfamide

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Randomised phase II study of siltuximab

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

✍ K. Fizazi; J.S. De Bono; A. Flechon; A. Heidenreich; E. Voog; N.B. Davis; Ming Q 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 336 KB